TITLE: Phase I Clinical Trial of a Vascular Disrupting Agent for AML and MDS

FACULTY MENTOR: Christopher R. Cogle, M.D. (c@ufl.edu)

RESEARCH PROJECT DESCRIPTION

BACKGROUND AND SIGNIFICANCE: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are common cancers of adulthood. Nearly all patients will die of refractory disease. We discovered that blood vessels are sanctuary sites for leukemia, and that targeting blood vessels regressed leukemia in experimental models.

HYPOTHESIS: Treating AML and MDS patients with vascular disrupting agents is safe and effective in remitting disease.

METHODS AND MATERIALS AND DATA ANALYSIS: Dr. Cogle has FDA IND approval to conduct a phase IA clinical trial of the vascular disrupting agent OXi4503 in patients with AML and MDS. The trial is a 3x3 dose escalation/de-escalation study. OXi4503 is administered weekly in Dr. Cogle’s leukemia clinic.

ROLE OF MEDICAL STUDENT: Medical students involved in this project will participate in subject recruitment, administration of investigational agent, safety monitoring, bone marrow aspirations and biopsies, and subject follow-up. The student will also participate in organizing data for presentations and manuscripts.

FUNDING SOURCES: Leukemia & Lymphoma Society, Gatorade Foundation

RELEVANT PUBLICATIONS:
